Pregled bibliografske jedinice broj: 864097
Assesment of BCR-ABL1 transcript levels at 3 months is the major determinant for outcome in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
Assesment of BCR-ABL1 transcript levels at 3 months is the major determinant for outcome in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors // European Journal of Cancer Abstract Book
Amsterdam: Elsevier, 2017. str. 772-772 doi:10.1016/S0959-8049(17)30412-4 (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 864097 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Assesment of BCR-ABL1 transcript levels at 3
months is the major determinant for outcome in
patients with chronic myeloid leukemia treated
with tyrosine kinase inhibitors
Autori
Katalinic, Darko
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
European Journal of Cancer Abstract Book
/ - Amsterdam : Elsevier, 2017, 772-772
Skup
European Cancer Congress
Mjesto i datum
Amsterdam, Nizozemska, 27.01.2017. - 30.01.2017
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
BCR-ABL1, chronic myeloid leukemia
Sažetak
Assesment of BCR-ABL1 transcript levels at 3 months is the major determinant for outcome in patients with chronic myelod leukemia treated with tyrpsine kinase inhibitors
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti, Dentalna medicina
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Osijek,
Fakultet za dentalnu medicinu i zdravstvo, Osijek
Profili:
Darko Katalinić
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE
